Takayasu Arteritis Clinical Trial in China

Summary

To investigate the efficacy and safety of Leflunomide (LEF) versus placebo combined with prednisone for active Takayasu arteritis (TAK) in Chinese population.

Timeline

Start

2016-12-22

Primary completion

2022-05-22

Completion

2022-11-22

Publications

• Sun Y, Kong X, Dai X, Wu R, Pan L, Wu L, Chen X, Yang P, Chen H, Ma L, Jin X, Zhang W, Jiang L. Efficacy of leflunomide in active Takayasu arteritis: a randomized double-blind placebo-controlled trial subtitle: Takayasu arteritis clinical trial in China (TACTIC). BMC Med. 2026 Jul 3. doi: 10.1186/s12916-026-05009-1. Online ahead of print.
• Sun Y, Wu B, Zhang W, Ma L, Kong X, Chen H, Jiang L. Comparison of the efficacy and safety of leflunomide versus placebo combined with basic prednisone therapy in patients with active disease phase of Takayasu arteritis: study protocol for a randomized, double-blinded controlled trial (Takayasu arteritis clinical trial in China: TACTIC). Ther Adv Chronic Dis. 2023 Mar 4;14:20406223231158567. doi: 10.1177/20406223231158567. eCollection 2023.

Drugs

Indications